This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Mar 1;10(5):1557-8.

doi: 10.1158/1078-0432.ccr-1217-3.

Cyclooxygenase inhibition as a target for prevention of tobacco-related cancers

PMID: 15014002
DOI: 10.1158/1078-0432.ccr-1217-3

Editorial

Cyclooxygenase inhibition as a target for prevention of tobacco-related cancers

Jay O Boyle. Clin Cancer Res. 2004.

. 2004 Mar 1;10(5):1557-8.

doi: 10.1158/1078-0432.ccr-1217-3.

Author

PMID: 15014002
DOI: 10.1158/1078-0432.ccr-1217-3

No abstract available

PubMed Disclaimer

Comment on

Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.
Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF Jr. Mulshine JL, et al. Clin Cancer Res. 2004 Mar 1;10(5):1565-73. doi: 10.1158/1078-0432.ccr-1020-3. Clin Cancer Res. 2004. PMID: 15014005 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems